Glioblastoma is already the most aggressive type of brain cancer, and it is classified as grade 4, the highest grade in the World Health Organization’s brain tumor grading system. There is no separate “staging” system for brain tumors the way there is for breast or lung cancer. When people say “stage 4 glioblastoma,” they are referring to this grade 4 designation. Median survival with standard treatment is 12 to 15 months, though some patients live significantly longer depending on tumor biology and treatment response.
Why It’s Called Grade 4, Not Stage 4
Most cancers use a staging system (stages 1 through 4) based on tumor size and whether cancer has spread to lymph nodes or distant organs. Brain tumors work differently. They almost never spread outside the brain, so that staging framework doesn’t apply. Instead, the WHO grades brain tumors from 1 to 4 based on how abnormal the cells look under a microscope and how quickly they grow. Grade 1 tumors are slow-growing and often curable with surgery. Grade 4 tumors are fast-growing, deeply invasive, and resistant to treatment.
Glioblastoma is always grade 4. Under the 2021 WHO classification, the official name is “glioblastoma, IDH-wildtype, CNS WHO grade 4.” The IDH-wildtype part means the tumor lacks a specific gene mutation (IDH) that would indicate a somewhat less aggressive form. Even tumors that initially look lower-grade under the microscope get reclassified as grade 4 glioblastoma if they carry certain molecular markers: a mutation in the TERT promoter gene, amplification of the EGFR gene, or a combined gain of chromosome 7 and loss of chromosome 10. These molecular features signal that the tumor will behave aggressively regardless of how it appears on a biopsy slide.
What Makes Glioblastoma So Aggressive
Glioblastoma originates from astrocytes, the star-shaped support cells in the brain. Unlike many solid tumors that grow as a contained mass, glioblastoma sends microscopic tendrils deep into surrounding brain tissue. This infiltrative growth pattern is the core reason the disease is so difficult to treat. Even when a surgeon removes every visible trace of tumor, invisible cancer cells remain embedded in functioning brain tissue.
At the molecular level, glioblastoma hijacks several of the body’s normal growth-control systems simultaneously. The most commonly disrupted pathway involves a receptor on the cell surface (EGFR) that normally regulates when cells grow and divide. In glioblastoma, this receptor is often overactive or present in too many copies, sending constant “grow” signals. At the same time, the tumor frequently disables two of the cell’s most important brakes on growth: the TP53 gene (which normally triggers damaged cells to self-destruct) and the RB pathway (which normally prevents cells from dividing uncontrollably). With growth signals stuck on and safety mechanisms knocked out, the tumor expands rapidly.
Glioblastoma is also remarkably heterogeneous. Different regions within a single tumor can behave in completely different ways. Some areas are rapidly dividing while others are relatively quiet. Some are rich with blood vessels while others are starved of oxygen and dying. This internal diversity makes it extremely difficult for any single therapy to kill every cancer cell.
Common Symptoms
Seizures are one of the most common first signs, occurring as the initial symptom in roughly 45% of patients. Overall, 20 to 50% of glioblastoma patients experience seizures at some point during their illness. These can range from full convulsions to subtler episodes like brief confusion, involuntary twitching in one limb, or a strange sensory experience.
Other symptoms depend on where in the brain the tumor is located. Headaches that worsen over days or weeks, particularly in the morning, often result from rising pressure inside the skull as the tumor and surrounding swelling take up space. Personality or cognitive changes, weakness on one side of the body, difficulty speaking, and vision problems are all common. Many patients or their families notice a gradual change in thinking, memory, or behavior before any other symptom appears.
How It’s Diagnosed
MRI with contrast dye is the primary imaging tool. On a scan, glioblastoma typically appears as an irregularly shaped mass with a bright ring of enhancement surrounding a dark center. That dark core represents necrosis, or dead tissue at the tumor’s center, which is a hallmark of grade 4 tumors. Surrounding the enhancing ring, there is usually significant swelling in the adjacent brain tissue.
Imaging alone cannot confirm the diagnosis. A tissue sample, obtained through either a biopsy or surgical removal, is tested for the molecular markers that define glioblastoma under the current classification: IDH mutation status, TERT promoter mutations, EGFR amplification, and chromosomal changes. These results determine both the official diagnosis and, critically, how well the tumor is likely to respond to chemotherapy.
Standard Treatment
Treatment follows a well-established three-part approach: surgery, radiation, and chemotherapy.
Surgery comes first, with the goal of removing as much tumor as possible without damaging critical brain functions. Research consistently shows that more complete removal translates to longer survival. Mathematical modeling suggests that removing at least 78% of the visible tumor is the minimum threshold for a survival benefit, with incremental gains continuing up to 98% or more. At one year after surgery, patients who had a complete visible removal were significantly less likely to have experienced tumor progression. Because glioblastoma infiltrates normal tissue, a true cure through surgery alone is not possible, but maximal removal reduces the tumor burden that subsequent treatments need to control.
After recovery from surgery (typically about four weeks), patients begin six weeks of daily radiation therapy combined with a daily oral chemotherapy drug called temozolomide. After another four-week break, temozolomide continues on its own for up to six additional monthly cycles.
How well temozolomide works depends heavily on a molecular feature of the tumor called MGMT promoter methylation. When this gene is “methylated,” or silenced, the tumor has a harder time repairing the DNA damage that temozolomide causes. Patients with a methylated MGMT promoter who receive the combined treatment have a median survival of about 21.7 months, compared to 15.3 months with radiation alone. For patients whose tumors lack this methylation, the benefit of adding temozolomide is much smaller, with progression-free survival of 5.3 months versus 4.4 months with radiation alone. MGMT status is one of the single most important factors in predicting how a patient will respond to standard treatment.
Tumor Treating Fields
A newer addition to glioblastoma treatment is a wearable device that delivers low-intensity electrical fields to the scalp. These alternating fields interfere with the internal machinery that cancer cells need to divide, disrupting the structures that pull chromosomes apart during cell division. Because healthy brain cells divide far less frequently than cancer cells, the treatment largely spares normal tissue.
In a large clinical trial, adding this therapy to standard temozolomide treatment extended median survival from 16.0 months to 20.9 months, a gain of nearly five months. Progression-free survival also improved, from 4.0 to 6.7 months. The device is worn on the head for at least 18 hours a day, which is a significant lifestyle adjustment, but it does not involve the nausea or immune suppression associated with traditional chemotherapy.
Prognosis and Survival
With the full standard treatment regimen, median survival for newly diagnosed glioblastoma is approximately 12 to 15 months. The two-year survival rate is below 30%, and the five-year survival rate is less than 10%. These numbers represent averages across a wide range of patients. Younger age, better overall health, more complete surgical removal, and a methylated MGMT promoter are all associated with longer survival.
The addition of tumor treating fields pushes median survival to around 20.9 months for eligible patients, currently the best outcome achievable with available therapies.
Recurrence
Glioblastoma recurs in nearly every patient. The average time before the tumor begins growing again is roughly 7 months from diagnosis. Once it recurs, prognosis drops sharply, with median survival at that point around 6 months.
Treatment options for recurrent glioblastoma are limited and no single standard approach exists. Only about 20 to 30% of patients are candidates for a second surgery. Repeat radiation is rarely used. The most common systemic option is lomustine, an older oral chemotherapy drug that has remained a mainstay for recurrence since its FDA approval in 1976. Bevacizumab, a drug that blocks blood vessel growth to the tumor, was approved by the FDA in 2009 for recurrent glioblastoma based on imaging response rates, though it has not been shown to extend overall survival. Immunotherapy drugs like nivolumab have been tested in clinical trials but have not outperformed existing options. In one large trial comparing nivolumab to bevacizumab, median survival was virtually identical at about 10 months in both groups.
At recurrence, the focus of care often shifts toward maintaining quality of life and managing symptoms, as treatments at this stage are generally palliative rather than curative.